Screener / SEC EDGAR /CIK 0000882796 /10-K filed Feb 26, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Biocryst Pharmaceuticals Inc BCRX

Compare with peers Embed
Cash returned and share count

No buyback or stock pay figures in its 10-K data yet

XBRL, 10-K

New shares against shares bought back

Dilution: new shares, stock pay and buybacks · S-3 and 424B, 3 years; 10-K

Shares offered

Since Nov 17, 2023: 1 registration of shares for a merger, units or notes, 1 shelf registration.

“424B3 ny20057110x3_424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-291678 PROPOSED MERGER — YOUR VOTE IS VERY IMPORTANT Dear Stockholders of Astria Therapeutics, Inc.: On October 14, 2025, BioCryst Pharmaceuticals, Inc., a Delaware corporation (“BioCryst”), Axel Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of BioCryst (“Merger Sub”), and Astria Therapeutics, Inc., a Delaware …”

424B3, Dec 18, 2025
Every offering filing

Paid in stock and bought back

No stock pay or buyback lines in the 10-K XBRL.

Where the cash came from and where it went

FY2025, from the cash flow statement in the 10-K, added up

Operating cash flowCash on hand usedCapital spendingDebt repaidOther, net Operating cash flow: $347.4M Operating cash flow $347.4M Cash on hand used: $15.0M Cash on hand used $15.0M Capital spending: $2.5M Capital spending $2.5M Debt repaid: $300.0M Debt repaid $300.0M Other, net: $59.9M Other, net $59.9M

Went to

Capital spending $2.5M
Debt repaid $300.0M
Other, net
investments bought and sold, other financing and investing lines, and exchange rates
$59.9M

Each number is a line of the cash flow statement as the company tagged it. "Other, net" is what those lines do not cover (investments bought and sold, other financing and investing lines, and exchange rates); Tickdelta does not estimate it.

Where the operating cash went, year by year

FY2016 to FY2025 · cash flow statements, 10-K XBRL

10 years
Operating cash, added up -$515.6M 10 fiscal years, FY2016 to FY2025
Reinvested - not shown: operating cash was negative in a year of the span
Returned to owners - not shown: operating cash was negative in a year of the span
Debt repaid $540.5M gross repayments added up; debt that was refinanced counts each time
Fiscal yearOperating cashCapital spendingDebt repaid
Dec 31, 2025 $347.4M $2.5M$300.0M
Dec 31, 2024 -$52.0M $1.1M-
Dec 31, 2023 -$95.1M $2.2M$240.5M
Dec 31, 2022 -$161.8M $1.4M-
Dec 31, 2021 -$142.2M $2.4M-
Dec 31, 2020 -$135.1M $514K-
Dec 31, 2019 -$89.6M $343K-
Dec 31, 2018 -$92.6M $366K-
Dec 31, 2017 -$41.1M $328K-
Dec 31, 2016 -$53.4M $5.3M-
Added up-$515.6M $16.3M$540.5M

Each bar is one fiscal year; its colours add up to what the cash flow statement says the company spent on each line, and the line across it is that year's operating cash flow. Spending above the line was paid from new debt, shares sold or cash on hand. A bar part links to the 10-K it comes from. A line the company did not report is left out, not estimated, so the shares are of operating cash only and can add up to more or less than 100%. Debt repaid is the gross amount, so refinanced debt is counted each time it is repaid. A reading aid, not a grade: Tickdelta does not say whether a split was good. Banks and insurers are left out.

Buybacks, dividends and share count

Year by year · XBRL, each 10-K

No buyback or share count data in the 10-K XBRL.

What the 10-Ks show for each CEO's years

Each CEO's years · the CEO of each fiscal year as named in the proxy's pay versus performance table

Jon P. Stonehouse (our principal executive officer (“PEO”) for the years reported)

FY2025 · 1 year in the table
Operating cash flow
$347.4M
Capital spending
$2.5M
Stock-based pay
$85.1M
Diluted shares since FY2024
+5.7%
Revenue since FY2024
+94%
Debt since FY2024
-$314.9M
CEO pay (reported)
$13.0M
The proxy that names the CEO

Sources

The cash flow statement, dividends per share and diluted share count in each 10-K's XBRL; Part II Item 2 of each 10-Q for monthly buybacks; offering prospectuses (S-3, 424B) for new shares; Form D data sets for private raises.

Also

CEO pay: what the CEO was paid over the same years.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BCRX/export.csv") into a cell.

Next:CEO pay
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.